In a report released yesterday, Gregory Renza from RBC Capital maintained a Buy rating on Nuvation Bio (NUVB – Research Report), with a price target of $5.00. The company’s shares closed yesterday at $3.30.
According to TipRanks, Renza is a 5-star analyst with an average return of 18.4% and a 47.06% success rate. Renza covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Alpine Immune Sciences, and ADC Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nuvation Bio with a $6.60 average price target, which is a 100.00% upside from current levels. In a report released yesterday, BTIG also maintained a Buy rating on the stock with a $5.00 price target.
NUVB market cap is currently $722.9M and has a P/E ratio of -9.53.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nuvation Bio (NUVB) Company Description:
Panacea Acquisition Corp is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
Read More on NUVB:
